JP2010513328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513328A5 JP2010513328A5 JP2009541713A JP2009541713A JP2010513328A5 JP 2010513328 A5 JP2010513328 A5 JP 2010513328A5 JP 2009541713 A JP2009541713 A JP 2009541713A JP 2009541713 A JP2009541713 A JP 2009541713A JP 2010513328 A5 JP2010513328 A5 JP 2010513328A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- acid
- api
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 239000008186 active pharmaceutical agent Substances 0.000 claims 12
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 10
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 10
- 229930003316 Vitamin D Natural products 0.000 claims 8
- 235000019166 vitamin D Nutrition 0.000 claims 8
- 239000011710 vitamin D Substances 0.000 claims 8
- 229940046008 vitamin d Drugs 0.000 claims 8
- -1 vitamin D compound Chemical class 0.000 claims 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 5
- 229960004977 anhydrous lactose Drugs 0.000 claims 5
- 229960001375 lactose Drugs 0.000 claims 5
- 239000008101 lactose Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- 239000004067 bulking agent Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 229960004343 alendronic acid Drugs 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- 235000005282 vitamin D3 Nutrition 0.000 claims 2
- 239000011647 vitamin D3 Substances 0.000 claims 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 2
- 229940021056 vitamin d3 Drugs 0.000 claims 2
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000003076 Osteolysis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 229920003072 Plasdone™ povidone Polymers 0.000 claims 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 claims 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 claims 1
- DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002286 clodronic acid Drugs 0.000 claims 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960004585 etidronic acid Drugs 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 229960005236 ibandronic acid Drugs 0.000 claims 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 229950004969 olpadronic acid Drugs 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- 229960003978 pamidronic acid Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 229960000759 risedronic acid Drugs 0.000 claims 1
- DUYCFMAOEDAKDN-UHFFFAOYSA-M sodium (4-amino-1-hydroxy-1-phosphonobutyl)-hydroxyphosphinate hydrate Chemical compound O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DUYCFMAOEDAKDN-UHFFFAOYSA-M 0.000 claims 1
- CAKRAHQRJGUPIG-UHFFFAOYSA-M sodium;[4-azaniumyl-1-hydroxy-1-[hydroxy(oxido)phosphoryl]butyl]-hydroxyphosphinate Chemical compound [Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O CAKRAHQRJGUPIG-UHFFFAOYSA-M 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 229960005324 tiludronic acid Drugs 0.000 claims 1
- 229960004276 zoledronic acid Drugs 0.000 claims 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2571398 | 2006-12-20 | ||
| CA2571538 | 2006-12-20 | ||
| PCT/CA2007/002313 WO2008074144A1 (en) | 2006-12-20 | 2007-12-19 | A composition containing a bisphosphonic acid in combination with vitamin d |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010513328A JP2010513328A (ja) | 2010-04-30 |
| JP2010513328A5 true JP2010513328A5 (enExample) | 2010-12-16 |
Family
ID=39535941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009541713A Pending JP2010513328A (ja) | 2006-12-20 | 2007-12-19 | ビタミンｄおよびビスホスホン酸を含有する組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100179110A1 (enExample) |
| EP (2) | EP2561877A1 (enExample) |
| JP (1) | JP2010513328A (enExample) |
| AU (1) | AU2007335155A1 (enExample) |
| CA (1) | CA2671727C (enExample) |
| WO (1) | WO2008074144A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210596A1 (en) * | 2009-01-22 | 2010-07-28 | Laboratorios Liconsa, S.A. | Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof |
| KR101230178B1 (ko) | 2010-06-10 | 2013-02-06 | 주식회사 네비팜 | 골다공증 예방 또는 치료용 조성물 및 이의 제조방법 |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| PT106978A (pt) | 2013-05-31 | 2014-12-02 | Tecnimede Sociedade Tecnico Medicinal S A | Composição sólida oral contendo ácido ibandrónico e vitamina d |
| GR1008440B (el) * | 2014-01-14 | 2015-03-05 | "Φαρματεν Α.Β.Ε.Ε.", | Φαρμακευτικο σκευασμα που περιλαμβανει συνδυασμο διφωσφωνικων και χοληκαλσιφερολης και μεθοδος για την παρασκευη αυτου |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3042531A (en) | 1959-12-09 | 1962-07-03 | Leslie Salt Company | Method of making a compressed tablet |
| US4330537A (en) * | 1977-12-07 | 1982-05-18 | The Procter & Gamble Company | Compositions for inhibiting mobilization of calcium phosphate in animal tissue |
| US4230700A (en) | 1977-12-07 | 1980-10-28 | The Procter & Gamble Company | Methods for inhibiting mobilization of calcium phosphate in animal tissue |
| DE3428524A1 (de) | 1984-08-02 | 1986-02-13 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| DE3512536A1 (de) | 1985-04-06 | 1986-10-16 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| DE3623397A1 (de) | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| DE3626058A1 (de) | 1986-08-01 | 1988-02-11 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| US5358941A (en) * | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| US6238697B1 (en) * | 1998-12-21 | 2001-05-29 | Pharmalogix, Inc. | Methods and formulations for making bupropion hydrochloride tablets using direct compression |
| PL366453A1 (en) * | 2001-05-01 | 2005-02-07 | Pfizer Products Inc. | Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency |
| US20030158154A1 (en) * | 2001-07-17 | 2003-08-21 | Moshe Fleshner-Barak | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
| JP2005513099A (ja) * | 2001-12-21 | 2005-05-12 | ファイザー・プロダクツ・インク | アジスロマイシンの直接的に圧縮可能な配合品 |
| US20050176685A1 (en) * | 2002-04-05 | 2005-08-11 | Daifotis Anastasia G. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| WO2004058235A2 (en) * | 2002-12-16 | 2004-07-15 | Teva Pharmaceutical Industries Ltd. | Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative |
| AU2004315136B2 (en) * | 2004-02-04 | 2010-06-17 | Alembic Limited | Extended release coated microtablets of venlafaxine hydrochloride |
| US20050261250A1 (en) * | 2004-05-19 | 2005-11-24 | Merck & Co., Inc., | Compositions and methods for inhibiting bone resorption |
| EP1758594A1 (en) | 2004-05-19 | 2007-03-07 | Merck and Co., Inc. | Combination for inhibiting bone resorption comprising a bisphosponate (alendrona) and a vitamin d (cholecalciferol) |
-
2007
- 2007-12-19 EP EP12174951A patent/EP2561877A1/en not_active Withdrawn
- 2007-12-19 JP JP2009541713A patent/JP2010513328A/ja active Pending
- 2007-12-19 EP EP20070855595 patent/EP2124963A4/en not_active Ceased
- 2007-12-19 CA CA2671727A patent/CA2671727C/en not_active Expired - Fee Related
- 2007-12-19 US US12/518,260 patent/US20100179110A1/en not_active Abandoned
- 2007-12-19 WO PCT/CA2007/002313 patent/WO2008074144A1/en not_active Ceased
- 2007-12-19 AU AU2007335155A patent/AU2007335155A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3725427B2 (ja) | ビホスホネートを含む経口医薬品組成物の製造方法 | |
| CN100551377C (zh) | 用于治疗和预防骨质疏松症的二膦酸 | |
| HU226457B1 (en) | Compositions containing diphosphonic acids | |
| AU2003250218B2 (en) | High dose Ibandronate formulation | |
| JP2004528303A5 (enExample) | ||
| JP2013500995A5 (enExample) | ||
| CA2438848A1 (en) | Compositions for delivering bisphosphonates | |
| JP2010513328A5 (enExample) | ||
| JP2010501538A5 (enExample) | ||
| WO2005030177A2 (en) | Pharmaceutical formulation with improved stability | |
| CA2517372C (en) | Pharmaceutical composition of alendronic acid, salts or esters thereof, and a process for its preparation | |
| WO2006018033A1 (en) | Formulations of bisphosphonates | |
| AU2007101091A4 (en) | Pharmaceutical formulation | |
| AU2006222690B2 (en) | High dose ibandronate formulation | |
| WO2008020305A2 (en) | Solid dosage forms of bisphosphonic acids | |
| MX2007014056A (es) | Composicion farmaceutica solida para administracion oral de acido ibandronico o una sal o un hidrato farmaceuticamente aceptable del mismo, procedimiento de preparacion de dicha composicion mediante compresion directa, formulaciones farmaceuticas que | |
| HK1080714B (en) | High dose ibandronate formulation |